Massive DOJ Probe — Top Med Schools Scrutinized

April 7, 2026

Elite medical schools face federal scrutiny for potentially discriminating against qualified Asian and white applicants through hidden racial preferences in admissions.

Story Highlights

DOJ launched Title VI investigations into Stanford, UCSD, and OSU medical schools on March 25, 2026, demanding seven years of detailed applicant data by April 24.
Trump administration leverages federal funding to enforce the 2023 Supreme Court ban on race-based admissions, targeting top NIH-funded institutions.
Schools must submit test scores, GPAs, demographics, essays, and internal race analyses, risking funding cuts for non-compliance.
Assistant AG Harmeet K. Dhillon confirmed the probes, signaling aggressive action against post-SFFA evasion tactics.

DOJ Launches Compliance Reviews

U.S. Department of Justice Civil Rights Division initiated investigations on March 25, 2026, into Stanford University, University of California San Diego, and Ohio State University medical schools. These probes examine possible race discrimination in admissions under Title VI of the Civil Rights Act of 1964. The DOJ demands comprehensive data from 2019 to 2026, including applicant test scores, GPAs, demographics, essays, extracurriculars, admissions outcomes, and policy documents. Universities face an April 24 deadline, with non-compliance threatening loss of federal funding. Ohio State publicly shared its letter, while UCSD and Stanford confirmed receipt and pledged review.

Post-Supreme Court Enforcement

The 2023 Supreme Court ruling in SFFA v. Harvard ended explicit racial preferences in college admissions, deeming race as a “plus factor” unconstitutional. Medical schools shifted to “holistic” reviews, yet disparities persist, such as lower MCAT scores for Black and Latino applicants at UCLA (506-509 medians versus 513-516 for whites and Asians). The Trump administration, prioritizing merit-based systems, expanded probes from UCLA lawsuits where DOJ joined in 2026. These actions build on precedents like Education Department demands on California systems, using NIH funding leverage against top recipients like Stanford and OSU.

Stakeholders and Power Dynamics

Assistant Attorney General Harmeet K. Dhillon leads the DOJ efforts, confirming the investigations via X on March 27 with a post stating, “We did this yesterday. Among other things!” Schools defend their processes as race-neutral and compliant, emphasizing fair holistic evaluations without MCAT minimums. Groups like Do No Harm and Students for Fair Admissions push for meritocracy, alleging systemic biases favoring underrepresented minorities. Pharma companies face scrutiny over diversity-tied grants. The federal government holds decisive power through funding threats, clashing with progressive California institutions resistant to change.

Conservatives applaud this pushback against what they see as reverse discrimination undermining individual achievement and medical competence. Liberals worry it hampers diversity in healthcare, potentially widening inequities. Both sides share frustration with elite universities prioritizing agendas over merit, echoing broader distrust in institutions that favor insiders over everyday Americans striving for the dream through hard work.

Potential Impacts and Broader Reach

Short-term effects include heavy compliance costs and data burdens for schools, with funding risks looming by April 24. Long-term, successful enforcement could force race-neutral admissions nationwide, setting precedents for other graduate programs and exposing pharma influences. Asian and white applicants stand to benefit from fairer competition, while minority enrollment may decline without preferences. This escalates political tensions between the Trump-led GOP government and blue-state academia, fueling culture war debates on merit versus equity. Ultimately, it challenges whether medical training serves patients through excellence or ideological goals.